TG Therapeutics (TGTX) Q1 2026 Earnings Transcript

TG Therapeutics delivered a strong Q1 with U.S. BRIUMVI net product revenue of $195 million, beating guidance of $185 million-$190 million, while total revenue reached $205 million and operating income rose to $34.8 million from $8.6 million a year ago. Management raised full-year U.S. revenue guidance to $885 million-$900 million and global revenue guidance to about $925 million, citing over 25,000 patients globally and continued strong persistence. The company also highlighted near-term catalysts in ENHANCE and subcutaneous BRIUMVI, plus aggressive buybacks of over 3 million shares in the quarter.

Analysis

TGTX is transitioning from a single-product launch story into a compounding installed-base story, which matters because the equity should start trading less like a binary biotech and more like a cash-generative specialty pharma with embedded operating leverage. The key second-order effect is that persistence converts each new cohort into a durable revenue annuity, so incremental demand has a larger impact on forward revenue than the market typically models at this stage. That also raises the value of the commercial infrastructure: once the fixed-cost base is built, every quarter of upside should flow disproportionately to operating income and buybacks.

The near-term setup is asymmetric because there are multiple catalysts in a short window, but the market may be underestimating how much of the current move is already tied to execution rather than optionality. ENHANCE is the cleaner catalyst because it can simplify initiation without adding manufacturing complexity, while the subcutaneous program is the real re-rating event because it opens an adjacent segment rather than taking marginal share. The risk is that investors extrapolate a smooth 2028 path for subcu too aggressively; bridging, device, and regulatory friction can easily push that economics out by 12-18 months, which would matter for a name trading on franchise duration.

The contrarian miss is that the best bull case may be less about peak-sales math and more about capital allocation. If management keeps buying stock while revenue growth outruns spend, per-share value compounds faster than headline revenue implies, especially with meaningful gross cash and leverage capacity. The main bear case is not competitive displacement overnight, but diminishing marginal returns from DTC and channel expansion if new starts slow before the lifecycle data can broaden the addressable market.

Key Decisions for Investors

• Long TGTX into the next 2-6 weeks of catalyst flow (ENHANCE + subcu bioavailability data): favorable setup for a 10-20% upside move if data de-risks the franchise, with downside largely tied to timing slippage rather than core demand collapse.
• Use pullbacks to build a medium-term long in TGTX vs short a basket of slower-growth specialty pharma names: the catalyst stack plus buybacks should keep per-share growth outpacing peers over the next 2-4 quarters.
• Buy TGTX Jan-2027 or Jan-2028 calls on weakness rather than outright shares if you want convexity around subcu approval and launch timing; max loss defined, upside meaningful if the market starts capitalizing the 2028 product line.
• If long already, sell a portion into strength after catalyst-driven spikes and hold the remainder for the 2026 guide-up cycle; the stock can re-rate on guidance, then fade if investors focus on the longer subcu timeline.
• Avoid shorting TGTX outright unless clinical data disappoints materially; the combination of recurring revenue, repurchases, and cash removes the classic small-cap biotech funding overhang that usually supports the bear case.